EGFR-targeting as a biological therapy: Understanding Nimotuzumab's clinical effects

Rolando Perez, Ernesto Moreno, Greta Garrido, Tania Crombet

Producción científica: Contribución a una revistaArtículo de revisiónrevisión exhaustiva

35 Citas (Scopus)

Resumen

Current clinical trials of epidermal growth factor receptor (EGFR)-targeted therapies are mostly guided by a classical approach coming from the cytotoxic paradigm. The predominant view is that the efficacy of EGFR antagonists correlates with skin rash toxicity and induction of objective clinical response. Clinical benefit from EGFR-targeted therapies is well documented; however, chronic use in advanced cancer patients has been limited due to cumulative and chemotherapy-enhanced toxicity. Here we analyze different pieces of data from mechanistic and clinical studies with the anti-EGFR monoclonal antibody Nimotuzumab, which provides several clues to understand how this antibody may induce a biological control of tumor growth while keeping a low toxicity profile. Based on these results and the current state of the art on EGFR-targeted therapies, we discuss the need to evaluate new therapeutic approaches using anti-EGFR agents, which would have the potential of transforming advanced cancer into a long-term controlled chronic disease.

Idioma originalInglés
Páginas (desde-hasta)2014-2031
Número de páginas18
PublicaciónCancers
Volumen3
N.º2
DOI
EstadoPublicada - jun. 2011
Publicado de forma externa

Huella

Profundice en los temas de investigación de 'EGFR-targeting as a biological therapy: Understanding Nimotuzumab's clinical effects'. En conjunto forman una huella única.

Citar esto